Treatment and outcomes of ewing sarcoma in Turkish Adults: A single centre experience

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 327-330

  Seker, Mehmet Metin ^a   Kos, Tugba ^b   Ozdemir, Nuriye ^c   Seker, Ayse ^d   Aksoy, Sercan ^e   Uncu, Dogan ^c   Zengin, Nurullah ^c  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b Alasehir State Hospital   (Turkey)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Department of Medical Oncology Mutki State Hospital   (Turkey)

^e HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Adult cases; Ewing sarcoma; Prognosis; Turkey

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMEN; ADULT; ARTICLE; DISEASE FREE SURVIVAL; EWING SARCOMA; FEMALE; HEAD AND NECK TUMOR; HUMAN; LIMB; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR; SPINAL CORD TUMOR; SURVIVAL RATE; THORAX; TURKEY (REPUBLIC); YOUNG ADULT;

ABDOMEN; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; RETROSPECTIVE STUDIES; SARCOMA, EWING; SOFT TISSUE NEOPLASMS; SPINAL NEOPLASMS; SURVIVAL RATE; THORAX; TURKEY; YOUNG ADULT;

EID: 84894057293     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.327     Document Type: Article

References (27)

1. Applebaum MA, Worch J, Matthay KK, et al (2011). Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer, 117, 3027-32.
2. Bacci G, Dallari D, McDonald D, et al (1989). Neoadjuvant chemotherapy for localized Ewing's sarcoma of the extremities: preliminary results of a protocol which uses surgery (alone or followed by radiotherapy) for local control. Tumori, 75, 456-62.
3. Bacci G, Ferrari S, Comandone A, et al (2000). Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol, 39, 111-6.
4. Balamuth N J, Womer RB (2010). Ewing's sarcoma. Lancet Oncol, 11, 184-92.
5. Baldini, EH, Demetri GD, Fletcher CD, et al (1999). Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg, 230, 79-86.
6. Barbieri E, Emiliani E, Zini G, et al (1990). Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys, 19, 1165-70.
7. Collier AB, 3rd Simpson L, Monteleone P (2011). Cutaneous Ewing sarcoma: report of 2 cases and literature review of presentation, treatment, and outcome of 76 other reported cases. J Pediatr Hematol Oncol, 33, 631-4.
8. Cotterill SJ, Ahrens S, Paulussen M, et al (2000). Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol, 18, 3108-14.
9. Fizazi K, Dohollou N, Blay JY, et al (1998). Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol, 16, 3736-43.
10. Granowetter L, Womer R, Devidas M, et al (2009). Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol, 27, 2536-41.
11. Grier HE, Krailo MD, Tarbell NJ, et al (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med, 348, 694-701.
12. Gupta AA, Pappo A, Saunders N, et al (2010). Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer, 116, 3189-94.
13. Iwamoto Y (2007). Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol, 37, 79-89.
14. Juergens H, Daw NC, Geoerger B, et al (2011). Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol, 29, 4534-40.
15. Jurgens, H, U Dirksen (2011). Ewing sarcoma treatment. Eur J Cancer, 47, 366-7.
16. Jurgens H, Exner U (1988). Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer, 61, 23-32.
17. Kolb EA, Kushner BH, Gorlick R, et al (2003). Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 21, 3423-30.
18. Kushner BH, Meyers PA (2001). How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol, 19, 870-80.
19. Obata H, Ueda T, Kawai A, et al (2007). Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer, 109, 767-75.
20. Oberlin O, Deley MC, Bui BN, et al (2001). Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer, 85, 1646-54.
21. Saeter G (2007). Ewing's sarcoma of bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 18, 79-80.
22. Schwartz GK, Tap WD, Qin LX, et al (2013). Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol, 14 371-82.
23. Scurr M, Judson I (2006). How to treat the Ewing's family of sarcomas in adult patients. Oncologist, 11, 65-72.
24. Shannon Orr W, Denbo JW, Billups CA, et al (2012). Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol, 19, 3816-22.
25. Subbiah V, Anderson P, Lazar AJ, et al (2009). Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol, 10, 126-40.
26. Tap WD, Demetri G, Barnette P, et al (2012). Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol, 30, 1849-56.
27. van Doorninck JA, Ji L, Schaub B, et al (2010). Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol, 28, 1989-94.